摘要
表皮生长因子受体(epithelial growth factor receptor,EGFR)突变是肺腺癌中最常见的驱动基因突变,除exon 20插入突变外,最常见的罕见EGFR突变包括分别位于exon 18的G719X(G719S、G719A、G719C和G719D替换突变)、exon 20的S768I和exon 21的L861Q及其复合突变,本文报道了一例EGFR G719X/S768I复合突变肺腺癌患者(T_(3)N_(3)M_(3),ⅢC期),老年男性,一线使用阿法替尼(每天40 mg)产生较好的治疗反应,并对阿法替尼相关文献进行了复习,以期为临床提供参考。
epithelial growth factor receptor(EGFR)mutations are the most common driver gene mutations in lung adenocarcinoma.Except for exon 20 insertions,the most common rare EGFR mutations include G719X(G719S,G719A,G719C and G719D substitutions)located in exon 18,respectively,S768I of exon 20,L861Q of exon 21,and their compound mutations.This paper reports a case of EGFR G719X/S768I compound mutation lung adenocarcinoma patient(T_(3)N_(3)M_(3),stageⅢC),an elderly male,who received afatinib as the first line(40 mg every day)produced a good curative effect,and the relevant literature of afatinib was reviewed to provide reference for clinical practice.
作者
纪文
安彩红
薛飞帆
张文
王克艳
JI Wen;AN Caihong;XUE Feifan;ZHANG Wen;WANG Keyan(Department of Pharmacy,Jiaozhou Central Hospital of Qingdao,Qingdao,Shandong,266300,China;Department of Pharmacy,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan,Shandong,250021,China)
出处
《当代医学》
2025年第9期162-167,共6页
Contemporary Medicine
